Orchestra Bio
3 known investors
Find your way into Orchestra Bio
202 people in our graph share verified history with the Orchestra Bio team — schools, employers, funds. One of them is your warm intro.
Orchestra is a platform that unifies scientific, operational, and financial data into a single intelligent environment serving biotech and research teams. It functions as both a system of record and intelligence layer to enable data-driven decision-making and operational alignment.
Also known as Orchestra
Founders & leadership
Investors · 3
Company profile
researched Aug 2026Orchestra Bio develops an intelligent management system for life sciences research and development, positioned as an agentic operations platform for drug development. The product spans three areas: unified planning, which includes centralized R&D roadmapping across leadership, programs and scientific groups plus financial modelling to forecast and analyze spend across R&D, operations and personnel; intelligent operations, which automatically tracks progress, risks and outcomes by interpreting meetings, documents and reports and tracks execution against plan in a single view; and decision support, comprising combinatorial scenario modelling across programs and budgets and an AI-powered knowledge base intended to make institutional knowledge usable in decision-making.
The company describes its system as aimed at biotech startups and scientific founders, helping them connect scientific planning with financial and operational planning as they move from academic research to company operations. The stated purpose of the software is to support drug development decisions relating to funding, timelines, scenarios and program dependencies. Company blog material addresses topics such as managing contract research organizations with agents, agents for scientific R&D, and the digital transformation of R&D from paper to cloud to agents.
Founding story
Ashoka Rajendra is described as founder and CEO of Orchestra Bio, which emerged from stealth with $20 million in funding and a focus on helping science entrepreneurs handle financial management and long-term planning.
Business model
Orchestra Bio sells software: an R&D management and planning system used by biotech and drug development organizations, with prospective customers directed to book a demo through the company website.
Traction
The company exited stealth with $20 million in funding, and in November 2025 MBC BioLabs announced Orchestra Bio as a new partner, noting Orchestra Bio had been a supporter of MBC BioLabs resident companies. Orchestra Bio is also listed in the portfolio of venture firm Attivo Partners.
Latest developments
In November 2025, MBC BioLabs announced a partnership with Orchestra Bio, deepening an existing relationship with the incubator's resident company community. Attivo Partners lists Orchestra Bio as a portfolio company under a 2025 entry.
▸Full profile — market position, technology, go-to-market, geography
Market position
Orchestra Bio positions itself as a system of record and intelligence layer for the business side of science, addressing R&D planning, finance and operations for biotech companies.
Technology
The platform combines planning and financial modelling tools with AI agents that interpret meetings, documents and reports to track progress and risk, run combinatorial scenario models across programs and budgets, and power a knowledge base built on institutional information.
Go-to-market
The company markets directly through its website with a demo request, publishes blog content on agent-based R&D operations, and builds presence in the biotech startup ecosystem, including a partnership with the MBC BioLabs incubator community and outreach to early-stage founders at events such as the Nucleate Summit.
Biotech startups and drug development organizations, particularly scientific founders transitioning from academia into company leadership, along with R&D program leaders, operations teams and executives responsible for budgets and portfolio planning.
Geography
Activity is centered in the San Francisco Bay Area through the partnership with MBC BioLabs, which operates lab locations in San Francisco and San Carlos, California.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 6
by search overlap
Companies competing with Orchestra Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 2
launches, deals, and filingsMBC BioLabs announced Orchestra Bio as a new partner joining its community, citing Orchestra Bio's prior support of MBC BioLabs resident companies.
Orchestra Bio emerged from stealth with $20 million in funding, positioning its software and guidance for science entrepreneurs managing budgets and long-term planning.
$20M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Orchestra Bioorchestra.bio · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Orchestra Bio do?
- Orchestra Bio builds an agentic R&D management and planning platform for biotech drug development teams.
- Who are Orchestra Bio's investors?
- Orchestra Bio's investors include 8VC, Andreessen Horowitz, Moonfire Ventures.